Literature DB >> 2422272

Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

L A Lampson, W F Hickey.   

Abstract

The expression of class I and class II MHC products in human brain was studied. Radioimmunoassay confirmed weak expression of HLA-A,B,C and beta 2-microglobulin (beta 2-m) in brain extract. Quantitative inhibition assay showed brain had 1/70 as much activity as spleen, per microgram of extract protein. Immunoblot assay confirmed that HLA chains and beta 2-m were present in the brain extract. Class II was not detected. Microscopic analysis was performed on eight brain biopsies. The histologic appearance ranged from "apparently normal," to the presence of reactive astrocytes, to the presence of glial tumor. In every case, HLA-A,B,C and beta 2-m activity was concentrated at blood vessel walls. Small and medium-sized vessels were uniformly stained. Cell body staining was not seen in neurons, glia, oligodendrocytes, microglia, reactive astrocytes, or the majority of glial tumor cells. Class II activity was seen in occasional cell bodies in both grey matter and white matter in the microscopic assays. These cells had the morphologic appearance of microglia or reactive astrocytes. Occasional blood vessels also showed class II activity. Unlike the class I activity, the class II blood vessel stain was often discontinuous. More class II+ cell bodies were seen in tumor-associated tissue.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422272

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

Review 1.  New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns.

Authors:  L A Lampson
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

Review 2.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 3.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

Review 4.  Astrocytes and intracerebral immune responses.

Authors:  E M Frohman; S van den Noort; S Gupta
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

5.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

Review 6.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

7.  Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.

Authors:  C A Kruse; P M Schiltz; D Bellgrau; Q Kong; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

9.  Role of CD8+ T cells in control of West Nile virus infection.

Authors:  Bimmi Shrestha; Michael S Diamond
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs.

Authors:  Wei Song; Avima M Ruder; Liangyuan Hu; Yufeng Li; Rong Ni; Wenshuo Shao; Richard A Kaslow; MaryAnn Butler; Jianming Tang
Journal:  PLoS One       Date:  2009-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.